David A. Siegel Puma Biotechnology, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 245,700 shares of PBYI stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

245,700

Previous 246,800 0.45%

Holding current value

$1.35 Million

Previous $730,000 15.34%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.74 - $3.72 $3,014 - $4,092	-1,100 Reduced 0.45%	245,700 $842,000
Q1 2025 May 15, 2025	BUY	$2.76 - $3.88 $137,724 - $193,612	49,900 Added 25.34%	246,800 $730,000
Q4 2024 Feb 14, 2025	BUY	$2.42 - $3.39 $86,878 - $121,701	35,900 Added 22.3%	196,900 $600,000
Q3 2024 Nov 14, 2024	BUY	$2.25 - $4.03 $57,600 - $103,168	25,600 Added 18.91%	161,000 $410,000
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.83 $350,108 - $699,017	-119,900 Reduced 46.96%	135,400 $441,000
Q1 2024 May 15, 2024	SELL	$4.29 - $7.4 $126,555 - $218,300	-29,500 Reduced 10.36%	255,300 $1.35 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $55,750 - $112,250	25,000 Added 9.62%	284,800 $1.23 Million
Q3 2023 Nov 14, 2023	SELL	$2.63 - $4.09 $223,024 - $346,832	-84,800 Reduced 24.61%	259,800 $683,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $93,600 - $128,880	-36,000 Reduced 9.46%	344,600 $1.22 Million
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $232,492 - $507,064	105,200 Added 38.2%	380,600 $1.18 Million
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $188,256 - $451,104	88,800 Added 47.59%	275,400 $1.16 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $103,512 - $175,104	45,600 Added 32.34%	186,600 $442,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $80,032 - $161,040	48,800 Added 52.93%	141,000 $402,000
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $83,496 - $127,008	39,200 Added 73.96%	92,200 $266,000
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $459,420 - $1.06 Million	-161,200 Reduced 75.26%	53,000 $161,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $468,078 - $662,934	70,600 Added 49.16%	214,200 $1.5 Million
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $720,196 - $930,320	80,200 Added 126.5%	143,600 $1.32 Million
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $594,692 - $864,142	63,400 New	63,400 $616,000
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $1.97 Million - $2.31 Million	-207,300 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $140,200 - $264,800	-20,000 Reduced 8.8%	207,300 $2.16 Million
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $704,616 - $1.63 Million	-112,200 Reduced 33.05%	227,300 $1.92 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $41,600 - $68,672	6,400 Added 1.92%	339,500 $2.97 Million
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $1.06 Million - $1.55 Million	120,700 Added 56.83%	333,100 $3.59 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $2.52 Million - $7.33 Million	204,900 Added 2732.0%	212,400 $2.7 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $155,775 - $317,775	7,500 New	7,500 $291,000
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $3.84 Million - $5.43 Million	-79,600 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $197,010 - $327,525	3,300 Added 4.33%	79,600 $5.42 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $4.65 Million - $6.56 Million	49,500 Added 184.7%	76,300 $7.54 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $1.93 Million - $3.21 Million	26,800	26,800 $3.21 Million

Others Institutions Holding PBYI

# of Institutions

126

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $250M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account